children
age
year
hospit
six
picu
rsv
infect
septemb
march
includ
picu
tertiari
care
hospit
south
korea
samsung
medic
center
smc
seoul
asan
medic
center
seoul
korea
univers
ansan
hospit
ansan
gachon
univers
gill
hospit
incheon
pusan
nation
univers
children
hospit
yangsan
ewha
woman
univers
seoul
diagnosi
rsv
infect
confin
rsv
detect
h
picu
admiss
rapid
rsv
antigen
test
multiplex
respiratori
viru
polymeras
chain
reaction
pcr
andor
viral
cultur
respiratori
specimen
nasopharyng
endotrach
aspir
patient
underli
diseas
rsv
infect
detect
h
picu
admiss
exclud
studi
approv
institut
review
board
samsung
medic
center
irb
particip
hospit
requir
inform
consent
assent
waiv
data
delet
modifi
prior
analysi
retrospect
review
medic
record
includ
age
gender
underli
diseas
rsv
subtyp
method
rsv
detect
presenc
sever
rsv
infect
lrti
defin
clinic
tachypnea
hypoxia
requir
oxygen
supplement
chest
radiolog
confirm
pneumon
infiltr
hyperinfl
upper
respiratori
tract
infect
urti
defin
respiratori
symptom
without
hypoxia
normal
chest
radiolog
analyz
clinic
outcom
picu
hospit
accord
risk
factor
clinic
outcom
paramet
length
picu
stay
preval
durat
mechan
ventil
support
rate
tracheostomi
day
mortal
patient
receiv
tracheostomi
assum
date
discontinu
ventil
support
date
transfer
gener
ward
high
risk
sever
rsv
infect
defin
base
previou
studi
guidelin
presenc
one
follow
risk
prematur
gestat
age
week
cld
caa
nmd
syndrom
profound
immunocompromis
also
analyz
medic
cost
picu
hospit
smc
south
korea
rsv
season
span
autumn
earli
spring
monitor
korea
influenza
respiratori
surveil
system
kinress
center
diseas
control
prevent
south
typic
pz
prophylaxi
could
initi
septemb
given
monthli
march
limit
maximum
number
five
dose
pz
introduc
first
cover
nation
healthcar
insur
servic
south
korea
infant
young
children
cld
sinc
januari
infant
sinc
infant
born
prematur
gestat
age
week
sinc
infant
born
gestat
age
week
addit
circumst
children
age
month
cover
sinc
septemb
indic
includ
studi
compar
elig
pz
prophylaxi
patient
year
age
guidelin
three
differ
countriesregion
south
korea
coverag
indic
palivizumab
guidelin
updat
decemb
european
medicin
agenc
ema
guidelin
synagi
european
public
assess
inform
updat
decemb
us
aap
guidelin
modifi
recommend
use
palivizumab
prevent
rsv
infect
detail
pz
prophylaxi
elig
criteria
list
tabl
depend
purpos
analysi
patient
classifi
accord
differ
age
criteria
use
age
rsv
infect
analysi
clinic
outcom
addit
age
begin
rsv
season
year
use
analysi
pz
prophylaxi
continu
variabl
categor
variabl
summar
median
rang
frequenc
percentag
respect
clinic
outcom
accord
risk
factor
compar
use
test
test
continu
variabl
fisher
exact
test
test
univari
analysi
multipl
linear
regress
analysi
multipl
logist
regress
analysi
perform
adjust
age
diagnosi
gender
rsv
infect
clinic
diseas
statu
multivari
analysi
continu
outcom
dunnett
test
appli
multipl
comparison
risk
group
group
multipl
linear
regress
p
consid
statist
signific
statist
analysi
carri
use
sa
version
sa
institut
cari
nc
usa
graphpad
prism
version
graphpad
softwar
la
jolla
ca
usa
total
pediatr
patient
admit
septemb
march
six
picu
rsv
detect
h
admiss
admiss
identifi
picu
admiss
six
exclud
reason
fig
six
picu
admiss
due
rsv
infect
due
sever
progress
statu
underli
diseas
two
patient
enceph
admit
picu
decreas
mental
statu
respiratori
tract
infect
three
patient
congenit
heart
diseas
admit
picu
plan
open
heart
surgeri
rsv
infect
found
routin
activ
surveil
evalu
median
age
picu
admiss
month
rang
month
iqr
month
tabl
patient
year
age
time
rsv
infect
almost
half
month
age
patient
male
underli
diseas
six
patient
receiv
pz
prior
rsv
infect
two
receiv
pz
day
prior
picu
admiss
patient
present
lrti
present
urti
median
length
picu
stay
day
rang
day
iqr
day
half
patient
requir
mechan
ventil
median
durat
mechan
ventil
day
rang
day
iqr
day
three
patient
requir
tracheostomi
overal
day
mortal
n
five
case
death
relat
sever
rsv
infect
tabl
five
patient
die
high
risk
sever
rsv
infect
two
two
cld
one
prematur
infant
gestat
age
week
monthli
distribut
picu
admiss
follow
season
pattern
rsv
circul
south
korea
increas
septemb
peak
octob
decemb
end
april
fig
rsv
season
septemb
march
picu
hospit
occur
patient
year
age
time
rsv
infect
year
age
begin
rsv
season
fig
patient
least
one
risk
factor
sever
rsv
infect
regardless
age
fig
picu
admiss
children
year
age
begin
rsv
season
common
risk
factor
follow
cld
caa
prematur
nmd
six
patient
underli
diseas
increas
risk
sever
rsv
infect
patient
underli
diseas
picu
admiss
children
year
age
time
rsv
infect
preval
mechan
ventil
significantli
higher
group
group
multivari
analysi
vs
p
signific
differ
howev
outcom
paramet
length
picu
stay
durat
mechan
ventil
requir
tracheostomi
day
mortal
nmdcaa
group
longer
median
durat
mechan
ventil
compar
group
day
rang
day
vs
day
rang
day
p
fig
tabl
estim
elig
pz
prophylaxi
accord
three
differ
guidelin
children
elig
pz
prophylaxi
base
guidelin
base
ema
guidelin
base
aap
guidelin
tabl
guidelin
appear
restrict
aap
guidelin
regard
pz
elig
differ
signific
vs
p
fig
medic
cost
analyz
patient
hospit
smc
children
year
old
time
rsv
infect
median
cost
health
care
group
appear
higher
group
although
differ
signific
rang
vs
rang
p
regard
patient
receiv
ventil
support
although
patient
risk
appear
higher
median
medic
cost
patient
risk
statist
signific
rang
vs
rang
p
tabl
studi
show
children
account
high
proport
picu
admiss
clinic
outcom
analysi
nmdcaa
associ
prolong
durat
mechan
ventil
elig
pz
prophylaxi
vari
accord
guidelin
differ
countri
proport
patient
picu
higher
studi
berger
et
al
report
intermedi
care
unit
imu
icu
admiss
children
year
age
switzerland
high
risk
least
one
risk
factor
prematur
gestat
age
week
cld
retrospect
studi
children
admit
picu
rsv
infect
canada
butt
et
al
found
underli
studi
howev
includ
nmdcaa
underli
diseas
nmdcaa
present
present
rsv
picu
case
preval
nmacaa
high
present
studi
compar
previou
studi
prematur
gestat
age
week
cld
rel
observ
might
due
differ
pz
prophylaxi
accord
risk
factor
differ
retrospect
studi
preterm
infant
gestat
age
week
south
korea
lee
et
al
report
preterm
infant
receiv
pz
prophylaxi
includ
high
pz
prophylaxi
rate
cld
prematur
infant
might
reduc
picu
admiss
group
present
studi
infant
nmdcaa
elig
pz
prophylaxi
south
korea
studi
report
pz
prophylaxi
rate
children
recent
studi
infant
south
korea
report
receiv
pz
prophylaxi
addit
present
studi
period
includ
rsv
season
patient
elig
pz
prophylaxi
result
pz
prophylaxi
mani
children
might
delay
furthermor
shown
present
studi
even
accord
restrict
guidelin
patient
alreadi
elig
pz
prophylaxi
receiv
six
patient
howev
receiv
pz
least
picu
admiss
due
rsv
infect
therefor
also
import
promot
adher
pz
prophylaxi
children
among
physician
daili
clinic
practic
current
pz
prophylaxi
guidelin
vari
greatli
countri
elig
pz
prophylaxi
present
patient
rang
base
guidelin
south
korea
eu
usa
main
differ
inclus
exclus
children
nmdcaa
differ
age
restrict
use
defin
prematur
age
restrict
use
identifi
children
base
mani
studi
prophylact
effect
contrast
children
nmdcaa
profound
immunocompromis
might
includ
current
guidelin
due
insuffici
data
effect
pz
prophylaxi
therefor
investig
prove
effect
pz
prophylaxi
group
need
addit
although
doubt
syndrom
risk
factor
sever
rsv
infect
remain
controversi
whether
pz
prophylaxi
efficaci
includ
therefor
studi
need
notabl
although
number
patient
small
n
median
durat
mechan
ventil
significantli
longer
children
nmdcaa
n
risk
day
rang
day
vs
day
rang
day
p
tabl
children
nmdcaa
also
like
receiv
tracheostomi
children
group
borderlin
signific
vs
p
defect
respiratori
defens
mechan
impair
abil
clear
secret
andor
insuffici
cough
due
weak
respiratori
muscl
barrier
wean
children
mechan
ventil
although
insuffici
patient
nmdcaa
show
cost
differ
prolong
ventil
support
mean
longer
picu
care
requir
addit
medic
resourc
therebi
gener
larger
socioeconom
burden
tabl
given
retrospect
studi
focus
hospit
like
children
sever
rsv
infect
sever
underli
diseas
includ
studi
includ
hospit
addit
despit
multicent
studi
design
number
case
insuffici
subgroup
analysi
due
rariti
diseas
nevertheless
studi
provid
need
data
proport
children
sever
rsv
infect
picu
pz
era
want
express
clinic
outcom
picu
admiss
due
sever
rsv
infect
includ
high
mortal
rate
well
econom
burden
picu
admiss
due
rsv
also
assess
elig
pz
prophylaxi
base
differ
guidelin
final
observ
children
nmdcaa
repres
signific
portion
picu
admiss
south
korea
children
elig
pz
prophylaxi
moreov
children
nmdcaa
appear
requir
prolong
durat
mechan
ventil
risk
therefor
worth
note
children
nmdcaa
might
compris
larger
portion
picu
admiss
pz
prophylaxi
appropri
given
children
alreadi
high
risk
accord
guidelin
conclus
south
korea
children
repres
higher
proport
picu
admiss
previous
report
studi
need
investig
burden
rsv
infect
picu
hospit
includ
associ
children
nmdcaa
receiv
grant
medimmun
rsv
research
receiv
grant
celltrion
research
monoclon
antibodi
contract
janssen
rsv
research
author
declar
conflict
interest
design
studi
carri
data
collect
analysi
draft
manuscript
conceptu
design
studi
critic
review
revis
manuscript
jl
hkc
sep
coordin
supervis
data
collect
hospit
critic
review
manuscript
sk
perform
analys
interpret
data
revis
manuscript
author
approv
final
manuscript
submit
agre
account
aspect
work
